Caitong International Asset Management Co., LTD Black Diamond Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $134 Billion
- Q1 2025
A detailed history of Caitong International Asset Management Co., LTD transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 3,560 shares of BDTX stock, worth $6,906. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,560Holding current value
$6,906% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
41MCall Options Held
45.1KPut Options Held
37K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$20.2 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$10.9 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$8.63 Million0.65% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$6.24 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$5.3 Million0.1% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $70.5M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...